8266 Federal Register / Vol. 77, No. 30 / Tuesday, February 14, 2012 / Notices 

bypasses the human metabolic 

machinery needed to convert the drug 

into its active metabolite(s). 

• Decreased CNS side effects. 

Development Stage: In vivo data 

available (animal). 

Inventors: Irving W. Wainer, Ph.D. 

(NIA), Carlos A. Zarate, M.D. (NIMH), 

Ruin Moaddel, Ph.D. (NIA), Michel 

Bernier (NIA), Michael E. Goldberg, 

M.D., Marc C. Toriman, Ph.D. 

Publications: 

1. Moaddel R, et al. A parallel chiralachiral liquid chromatographic 

method for the determination of the 

stereoisomers of ketamine and 

ketamine metabolites in the plasma 

and urine of patients with complex 

regional pain syndrome. Talanta. 

2010 Oct. 15;82(5):1892–1904. 

[PMID 20875593] 

2. Zarate CA Jr., et al. Relationship of 

Ketamine’s Plasma Metabolites with 

Response and Diagnosis, and Side 

Effects in Major Depression. 

Manuscript in preparation. 

3. Ibrahim L, et al. Course of 

Improvement in Depressive 

Symptoms to a Single Intravenous 

Infusion of Ketamine vs. Add-on 

Riluzole: Results from a Four-Week, 

Double-Blind, Placebo-Controlled 

Study. Neuropsychopharmacology, 

in press. 

4. Zhao X, et al. Population 

Pharmacokinetic Modeling of 

Ketamine and Three Major 

Metabolites in Patients with 

Treatment-Resistant Bipolar 

Depression. Br. J. Clin. Phamaco., in 

press. 

Intellectual Property: HHS Reference 

No. E–092–2011/0—U.S. Provisional 

Application No. 61/547,336 filed 14 

Oct. 2011. 

Related Technologies: HHS Reference 

No. E–174–2006/0— 

• U.S. Patent Application No. 11/ 

688,603 filed 20 Mar. 2007 

• Related international applications 

Licensing Contact: Jaime M. Greene, 

M.S.; 301–435–5559; 

greenejaime@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute on Aging, 

Laboratory of Clinical Investigation, 

Bioanalytical Chemistry and Drug 

Discovery Section, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Nicole Guyton, Ph.D. at 

darackn@mail.nih.gov. 

Improved DNA-Protein Vaccination 

Protocols 

Description of Technology: Nucleic 

acid based vaccines are attractive 

alternatives to conventional vaccines for 

a number of reasons. One of the issues 

with nucleic acid based vaccines is the 

poor immunogenicity in humans. The 

subject technology is a method for 

eliciting improved immune responses 

with DNA based vaccines. The method 

involves co-administration of a nucleic 

acid vaccine with a protein vaccine for 

the same antigen of interest that is 

encoded by the DNA vaccine in a primeboost protocol. This methodology 

increased the immune responses in a 

SIV macaque model to examine DNA 

based vaccines of HIV and vaccine 

protocols. The methodology can 

potentially be applied to other disease 

indications to elicit greater immune 

responses. 

Potential Commercial Applications: 

Improve immunogenicity of nucleic 

acid based vaccines. 

Competitive Advantages: The 

methodology increases the immune 

response of DNA based vaccines. 

Development Stage: 

• Early-stage 

• Pre-clinical 

• In vitro data available 

• In vivo data available (animal) 

Intellectual Property: HHS Reference 

No. E–239–2009/0—International PCT 

Application No. PCT/US2011/026325 

filed 25 Feb. 2011. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Dated: February 8, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–3412 Filed 2–13–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended, 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Eye Institute, including 

consideration of personnel 

qualifications and performances, and 

the competence of individual 

investigators, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Eye Institute. 

Date: March 4–5, 2012. 

Time: 7:00 PM to 5:00 PM. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Bethesda, MD 

20892. 

Contact Person: Sheldon S. Miller, Ph.D., 

Scientific Director, National Institutes of 

Health, National Eye Institute, Bethesda, MD 

20892, (301) 451–6763. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nei.nih.gov, where an agenda and any 

additional information will be posted when 

available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: February 8, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–3432 Filed 2–13–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

mstockstill on DSK4VPTVN1PROD with NOTICES